P
Philip A. Poole-Wilson
Researcher at National Institutes of Health
Publications - 443
Citations - 69648
Philip A. Poole-Wilson is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Heart failure & Heart disease. The author has an hindex of 105, co-authored 443 publications receiving 66861 citations. Previous affiliations of Philip A. Poole-Wilson include Harefield Hospital & St George's Hospital.
Papers
More filters
Journal ArticleDOI
Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET.
Philip A. Poole-Wilson,John G.F. Cleland,Andrea Di Lenarda,Peter Hanrath,Michel Komajda,Marco Metra,Willem J. Remme,Karl Swedberg,Christian Torp-Pedersen +8 more
TL;DR: The rationale, design and possible outcomes of COMET are outlined, which is the first study to investigate whether beta‐blocking agents with differing pharmacological profiles exert different effects on morbidity and mortality in patients with chronic heart failure.
Journal ArticleDOI
Haemoglobin concentration and prognosis in new cases of heart failure
Paul R. Kalra,Timothy Collier,Martin R. Cowie,Kevin Fox,David R. Wood,Philip A. Poole-Wilson,Andrew J.S. Coats,George C. Sutton +7 more
TL;DR: Hemoglobin was not independently associated with prognosis when age and serum creatinine concentration were included in the analysis, suggesting the adverse effects of anaemia on survival might be a consequence of chronic heart failure rather than a separate process causing disease progression.
Journal ArticleDOI
Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial.
Alain Cohen-Solal,Dipak Kotecha,Dirk J. van Veldhuisen,Daphne Babalis,Michael Böhm,Andrew J.S. Coats,Michael Roughton,Philip A. Poole-Wilson,Luigi Tavazzi,Marcus Flather +9 more
TL;DR: To determine the safety and efficacy of nebivolol in elderly heart failure (HF) patients with renal dysfunction, a large number of patients with kidney dysfunction are treated with this drug.
Journal ArticleDOI
Adherence and perception of medication in patients with chronic heart failure during a five-year randomised trial.
Inger Ekman,Gull Andersson,Kurt Boman,Andrew Charlesworth,John G.F. Cleland,Philip A. Poole-Wilson,Karl Swedberg +6 more
TL;DR: Belief in medication may be related to how the patient experiences the medication's impact on functional ability, symptoms and well-being and early identification of patients' beliefs about medication seem to be an important factor in counselling and information to patients with CHF.
Journal ArticleDOI
Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial.
Daniela Dobre,Dirk J. van Veldhuisen,Giacomo Mordenti,Marius Vintila,Flora M. Haaijer-Ruskamp,Andrew J.S. Coats,Philip A. Poole-Wilson,Marcus Flather +7 more
TL;DR: The benefits of nebivolol in elderly patients with HF appear to be related to the maintenance dose achieved, and patients unable to tolerate any dose had an increased risk of death or CV hospitalization.